Intelligence Feed event · Macro · 2026-10-01

    Survodutide Hits 13.1% Weight Loss in Phase III Obesity/Type 2 Diabetes Trial

    Question

    Survodutide Hits 13.1% Weight Loss in Phase III Obesity/Type 2 Diabetes Trial

    Direct answer

    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the Phase III SYNCHRONIZE-2 study evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants on survodutide achieved up to 13.1% body weight reduction compared to 3.1% on placebo. The dual mechanism glucagon/GLP-1 agonist also demonstrated significant reductions in HbA1c, reinforcing its competitive position within the metabolic disease treatment market.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Hits 13.1% Weight Loss in Phase III Obesity/Type 2 Diabetes Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-hits-13-1-weight-loss-in-phase-iii-obesity-type-2-diabetes-trial-69b680

    MACRO
    Survodutide Hits 13.1% Weight Loss in Phase III Obesity/Type 2 Diabetes Trial
    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the Phase III SYNCHRONIZE-2 study evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants on survodutide achieved up to 13.1% body weight reduction compared to 3.1% on placebo. The dual mechanism glucagon/GLP-1 agonist also demonstrated significant reductions in HbA1c, reinforcing its competitive position within the metabolic disease treatment market.
    ZLDPY
    Impact
    77
    OCT 1
    SIG
    90%
    ZLDPY
    Survodutide Hits 13.1% Weight Loss in Phase III Obesity/Type 2 Diabetes Trial
    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the Phase III SYNCHRONIZE-2 study evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants on survodutide achieved up to 13.1% body weight reduction compared to 3.1% on placebo. The dual mechanism glucagon/GLP-1 agonist also demonstrated significant reductions in HbA1c, reinforcing its competitive position within the metabolic disease treatment market.
    → Phase III clinical efficacy of 13.1% weight loss validates commercial viability and advances regulatory filing timelines for ZLDPY's royalty pipeline.
    Impact
    Boehringer Ingelheim and development partner Zealand Pharma published top-line data from the Phase III SYNCHRONIZE-2 study evaluating survodutide in adults with obesity and type 2 diabetes. At 76 weeks, participants on survodutide achieved up to 13.1% body weight reduction compared to 3.1% on placebo. The dual mechanism glucagon/GLP-1 agonist also demonstrated significant reductions in HbA1c, reinforcing its competitive position within the metabolic disease treatment market.
    Affected
    ZLDPY
    Transmission
    Phase III clinical efficacy of 13.1% weight loss validates commercial viability and advances regulatory filing timelines for ZLDPY's royalty pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYPhase III milestone validation and future royalty cash flowsUp1-5dZealand Pharma co-develops survodutide with Boehringer Ingelheim.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month